Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

341 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
3T multiparametric MRI-guided high-dose-rate combined intracavitary and interstitial adaptive brachytherapy for the treatment of cervical cancer with a novel split-ring applicator.
Fredman E, Traughber B, Podder T, Colussi V, Zheng Y, Russo S, Herrmann K, Paspulati R, Waggoner S, Zanotti K, Nagel C, Nakayama J, Machtay M, Ellis R. Fredman E, et al. Among authors: nagel c. Brachytherapy. 2018 Mar-Apr;17(2):334-344. doi: 10.1016/j.brachy.2017.09.007. Epub 2017 Oct 31. Brachytherapy. 2018. PMID: 29097137
Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.
Fader AN, Nagel C, Axtell AE, Zanotti KM, Kelley JL, Moore KN, Secord AA, Walsh CS, Huh WK, Gehrig PA, Gibbons H, Rose PG, Havrilesky LJ, Tuller E, Drake RD, Bottsford-Miller J, O'Malley DM; UPSC Consortium. Fader AN, et al. Among authors: nagel c. Gynecol Oncol. 2009 Mar;112(3):558-62. doi: 10.1016/j.ygyno.2008.11.016. Epub 2009 Jan 1. Gynecol Oncol. 2009. PMID: 19118888
The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis.
Taylor SE, O'Connor CM, Wang Z, Shen G, Song H, Leonard D, Sangodkar J, LaVasseur C, Avril S, Waggoner S, Zanotti K, Armstrong AJ, Nagel C, Resnick K, Singh S, Jackson MW, Xu W, Haider S, DiFeo A, Narla G. Taylor SE, et al. Among authors: nagel c. Cancer Res. 2019 Aug 15;79(16):4242-4257. doi: 10.1158/0008-5472.CAN-19-0218. Epub 2019 May 29. Cancer Res. 2019. PMID: 31142515 Free PMC article.
NCCN Guidelines Insights: Cervical Cancer, Version 1.2020.
Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Giuntoli R, Han E, Huh WK, Lurain Iii JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Sisodia R, Tillmanns T, Ueda S, Urban R, Wyse E, McMillian NR, Motter AD. Abu-Rustum NR, et al. Among authors: nagel c. J Natl Compr Canc Netw. 2020 Jun;18(6):660-666. doi: 10.6004/jnccn.2020.0027. J Natl Compr Canc Netw. 2020. PMID: 32502976
Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Cohn DE, Sill MW, Walker JL, O'Malley D, Nagel CI, Rutledge TL, Bradley W, Richardson DL, Moxley KM, Aghajanian C. Cohn DE, et al. Among authors: nagel ci. Gynecol Oncol. 2017 Sep;146(3):477-483. doi: 10.1016/j.ygyno.2017.07.135. Epub 2017 Jul 27. Gynecol Oncol. 2017. PMID: 28756871 Free PMC article. Clinical Trial.
341 results